Viral vectors for gene delivery to the central nervous system

Neurobiology of Disease

Volumn 48, Issue 2, 2012, Pages 179-188

  Lentz, Thomas B ^a   Gray, Steven J ^a   Samulski, R Jude ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Adeno associated virus; Adenovirus; Central nervous system; Gene therapy; Herpesvirus; Retrovirus; Viral vectors

Indexed keywords

ADENOVIRUS VECTOR; HERPESVIRUS VECTOR; LENTIVIRUS VECTOR; MOLONEY LEUKEMIA VIRUS VECTOR; NERVE GROWTH FACTOR; PARVOVIRUS VECTOR; RETROVIRUS VECTOR; UNCLASSIFIED DRUG; VIRUS VECTOR;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CARCINOGENICITY; CENTRAL NERVOUS SYSTEM; DISEASE SEVERITY; EPILEPSY; GENE EXPRESSION; GENE PRODUCT; GENE TARGETING; GENE THERAPY; HUMAN; INFECTION RISK; INFECTION SENSITIVITY; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; PATIENT SAFETY; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SEROTYPE; SYMPTOM; TARGET CELL; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENETICS; VIRION; VIRUS CAPSID; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS INHIBITION; VIRUS MUTATION; VIRUS RECOMBINATION; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSCRIPTION; VIRUS TRANSMISSION; VIRUS VIRULENCE;

ANIMALS; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASES; DEPENDOVIRUS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HERPESVIRIDAE; HUMANS; RETROVIRIDAE; RNA, VIRAL; VIRUSES;

EID: 84865570079     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2011.09.014     Document Type: Review

References (200)

1. Afione S.A., et al. In vivo model of adeno-associated virus vector persistence and rescue. J. Virol. 1996, 70:3235-3241.
2. Akache B., et al. The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J. Virol. 2006, 80:9831-9836.
3. Alisky J.M., et al. Transduction of murine cerebellar neurons with recombinant FIV and AAV5 vectors. Neuroreport 2000, 11:2669-2673.
4. Amalfitano A., et al. Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. J. Virol. 1998, 72:926-933.
5. Anderson D.B., et al. Pseudotyping of glycoprotein D-deficient herpes simplex virus type 1 with vesicular stomatitis virus glycoprotein G enables mutant virus attachment and entry. J. Virol. 2000, 74:2481-2487.
6. Andreansky S., et al. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res. 1997, 57:1502-1509.
7. Apolonia L., et al. Stable gene transfer to muscle using non-integrating lentiviral vectors. Mol. Ther. 2007, 15:1947-1954.
8. Armentano D., et al. Characterization of an adenovirus gene transfer vector containing an E4 deletion. Hum. Gene Ther. 1995, 6:1343-1353.
9. Atchison R.W., et al. Adenovirus-Associated Defective Virus Particles. Science 1965, 149:754-756.
10. Bayer M., et al. A large U3 deletion causes increased in vivo expression from a nonintegrating lentiviral vector. Mol. Ther. 2008, 16:1968-1976.
11. Bearer E.L., et al. Retrograde axonal transport of herpes simplex virus: evidence for a single mechanism and a role for tegument. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:8146-8150.
12. Bell P., et al. No evidence for tumorigenesis of AAV vectors in a large-scale study in mice. Mol. Ther. 2005, 12:299-306.
13. Bell P., et al. Analysis of tumors arising in male B6C3F1 mice with and without AAV vector delivery to liver. Mol. Ther. 2006, 14:34-44.
14. Bergelson J.M., et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997, 275:1320-1323.
15. Berk A.J. Adenoviridae: The Viruses and Their Replication. Fields virology 2007, 2355-2394. Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia. D.M. Knipe, P.M. Howley (Eds.).
16. Berns K.I., Parrish C.R. Parvoviridae. Fields Virology 2007, 2437-2477. Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia. B.N. Fields (Ed.).
17. Bessis N., et al. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther. 2004, 11(Suppl. 1):S10-S17.
18. Bett A.J., et al. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:8802-8806.
19. Bischof D., Cornetta K. Flexibility in cell targeting by pseudotyping lentiviral vectors. Methods Mol. Biol. 2010, 614:53-68.
20. Boehmer P.E., Lehman I.R. Herpes simplex virus DNA replication. Annu. Rev. Biochem. 1997, 66:347-384.
21. Bokhoven M., et al. Insertional gene activation by lentiviral and gammaretroviral vectors. J. Virol. 2009, 83:283-294.
22. Briggs J.A., et al. Structural organization of authentic, mature HIV-1 virions and cores. EMBO J. 2003, 22:1707-1715.
23. Broekman M.L., et al. Adeno-associated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or -2 serotypes for widespread gene delivery to the neonatal mouse brain. Neuroscience 2006, 138:501-510.
24. Brown P.O., et al. Retroviral integration: structure of the initial covalent product and its precursor, and a role for the viral IN protein. Proc. Natl. Acad. Sci. U. S. A. 1989, 86:2525-2529.
25. Bukrinsky M.I., et al. A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature 1993, 365:666-669.
26. Burger C., et al. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol. Ther. 2004, 10:302-317.
27. Candolfi M., et al. Effective high-capacity gutless adenoviral vectors mediate transgene expression in human glioma cells. Mol. Ther. 2006, 14:371-381.
28. Candolfi M., et al. Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro. Neuro Oncol. 2007, 9:245-258.
29. Cara A., Reitz M.S. New insight on the role of extrachromosomal retroviral DNA. Leukemia 1997, 11:1395-1399.
30. Cassinotti P., et al. Organization of the adeno-associated virus (AAV) capsid gene: mapping of a minor spliced mRNA coding for virus capsid protein. Virology 1988, 167:176-184.
31. Chao H., et al. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol. Ther. 2000, 2:619-623.
32. Chen S.T., et al. Generation of packaging cell lines for pseudotyped retroviral vectors of the G protein of vesicular stomatitis virus by using a modified tetracycline inducible system. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:10057-10062.
33. Chen J., et al. High efficiency of HIV-1 genomic RNA packaging and heterozygote formation revealed by single virion analysis. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:13535-13540.
34. Chen Y.H., et al. Molecular signatures of disease brain endothelia provide new sites for CNS-directed enzyme therapy. Nat. Med. 2009, 15:1215-1218.
35. Cheung A.K., et al. Integration of the adeno-associated virus genome into cellular DNA in latently infected human Detroit 6 cells. J. Virol. 1980, 33:739-748.
36. Chirmule N., et al. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther. 1999, 6:1574-1583.
37. Cockrell A.S., et al. A trans-lentiviral packaging cell line for high-titer conditional self-inactivating HIV-1 vectors. Mol. Ther. 2006, 14:276-284.
38. Colin A., et al. Engineered lentiviral vector targeting astrocytes in vivo. Glia 2009, 57:667-679.
39. Cornu T.I., Cathomen T. Targeted genome modifications using integrase-deficient lentiviral vectors. Mol. Ther. 2007, 15:2107-2113.
40. Danos O., Mulligan R.C. Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:6460-6464.
41. Davidson B.L., et al. Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:3428-3432.
42. Davison A.J., et al. Genetic content and evolution of adenoviruses. J. Gen. Virol. 2003, 84:2895-2908.
43. de Marco A., et al. Structural analysis of HIV-1 maturation using cryo-electron tomography. PLoS Pathog. 2010, 6:e1001215.
44. Desmaris N., et al. Production and neurotropism of lentivirus vectors pseudotyped with lyssavirus envelope glycoproteins. Mol. Ther. 2001, 4:149-156.
45. Dong J.Y., et al. Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Hum. Gene Ther. 1996, 7:2101-2112.
46. Dong B., et al. Characterization of genome integrity for oversized recombinant AAV vector. Mol. Ther. 2010, 18:87-92.
47. Duan D., et al. Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J. Virol. 1998, 72:8568-8577.
48. Duan D., et al. A new dual-vector approach to enhance recombinant adeno-associated virus-mediated gene expression through intermolecular cis activation. Nat. Med. 2000, 6:595-598.
49. Duan D., et al. Expanding AAV packaging capacity with trans-splicing or overlapping vectors: a quantitative comparison. Mol. Ther. 2001, 4:383-391.
50. Dull T., et al. A third-generation lentivirus vector with a conditional packaging system. J. Virol. 1998, 72:8463-8471.
51. Duque S., et al. Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol. Ther. 2009, 17:1187-1196.
52. Epstein A.L. HSV-1-derived amplicon vectors: recent technological improvements and remaining difficulties-a review. Mem. Inst. Oswaldo Cruz 2009, 104:399-410.
53. Escors D., Breckpot K. Lentiviral vectors in gene therapy: their current status and future potential. Arch. Immunol. Ther. Exp. (Warsz.) 2010, 58:107-119.
54. Everts M., Curiel D.T. Transductional targeting of adenoviral cancer gene therapy. Curr. Gene Ther. 2004, 4:337-346.
55. Ferrari F.K., et al. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J. Virol. 1996, 70:3227-3234.
56. Forster F., et al. Retrovirus envelope protein complex structure in situ studied by cryo-electron tomography. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:4729-4734.
57. Foust K.D., Kaspar B.K. Over the barrier and through the blood: to CNS delivery we go. Cell Cycle 2009, 8:4017-4018.
58. Foust K.D., et al. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol. 2009, 27:59-65.
59. Fraefel C., et al. Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells. J. Virol. 1996, 70:7190-7197.
60. Freed E.O. HIV-1 gag proteins: diverse functions in the virus life cycle. Virology 1998, 251:1-15.
61. Friedmann T., Roblin R. Gene therapy for human genetic disease?. Science 1972, 175:949-955.
62. Garber D.A., et al. Demonstration of circularization of herpes simplex virus DNA following infection using pulsed field gel electrophoresis. Virology 1993, 197:459-462.
63. Germano I.M., et al. Adenovirus/herpes simplex-thymidine kinase/ganciclovir complex: preliminary results of a phase I trial in patients with recurrent malignant gliomas. J. Neurooncol 2003, 65:279-289.
64. Ghosh A., et al. Efficient transgene reconstitution with hybrid dual AAV vectors carrying the minimized bridging sequences. Hum. Gene Ther. 2011, 22:77-83.
65. Gijsbers R., et al. LEDGF hybrids efficiently retarget lentiviral integration into heterochromatin. Mol. Ther. 2010, 18:552-560.
66. Glasgow J.N., et al. Transductional targeting of adenovirus vectors for gene therapy. Cancer Gene Ther. 2006, 13:830-844.
67. Goff S.P. Retroviridae: The Retroviruses and Their Replication. Fields Virology 2007, 2000-2069. Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia. D.M. Knipe, P.M. Howley (Eds.).
68. Gray S.J., et al. Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB). Mol. Ther. 2010, 18:570-578.
69. Gray S.J., et al. Viral vectors and delivery strategies for CNS gene therapy. Ther. Deliv. 2010, 1:517-534.
70. Gray S.J., et al. Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol. Ther. 2011, 19:1058-1069.
71. Greenberg K.P., et al. Targeted transgene expression in muller glia of normal and diseased retinas using lentiviral vectors. Invest. Ophthalmol. Vis. Sci. 2007, 48:1844-1852.
72. Grieger J.C., et al. Production and characterization of adeno-associated viral vectors. Nat. Protoc. 2006, 1:1412-1428.
73. Griffiths R.A., et al. Herpesvirus saimiri-based gene delivery vectors. Curr. Gene Ther. 2006, 6:1-15.
74. Grunewald K., et al. Three-dimensional structure of herpes simplex virus from cryo-electron tomography. Science 2003, 302:1396-1398.
75. Hacein-Bey-Abina S., et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003, 302:415-419.
76. Hearing P., et al. Identification of a repeated sequence element required for efficient encapsidation of the adenovirus type 5 chromosome. J. Virol. 1987, 61:2555-2558.
77. Hewitt F.C., Samulski R.J. Creating a novel origin of replication through modulating DNA-protein interfaces. PLoS One 2010, 5:e8850.
78. Hewitt F.C., et al. Reducing the risk of adeno-associated virus (AAV) vector mobilization with AAV type 5 vectors. J. Virol. 2009, 83:3919-3929.
79. Hillgenberg M., et al. Chromosomal integration pattern of a helper-dependent minimal adenovirus vector with a selectable marker inserted into a 27.4-kilobase genomic stuffer. J. Virol. 2001, 75:9896-9908.
80. Hirsch M.L., et al. AAV recombineering with single strand oligonucleotides. PLoS One 2009, 4:e7705.
81. Hirsch M.L., et al. Little vector, big gene transduction: fragmented genome reassembly of adeno-associated virus. Mol. Ther. 2010, 18:6-8.
82. Im D.S., Muzyczka N. The AAV origin binding protein Rep68 is an ATP-dependent site-specific endonuclease with DNA helicase activity. Cell 1990, 61:447-457.
83. Im D.S., Muzyczka N. Partial purification of adeno-associated virus Rep78, Rep52, and Rep40 and their biochemical characterization. J. Virol. 1992, 66:1119-1128.
84. Immonen A., et al. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol. Ther. 2004, 10:967-972.
85. Jager L., Ehrhardt A. Persistence of high-capacity adenoviral vectors as replication-defective monomeric genomes in vitro and in murine liver. Hum. Gene Ther. 2009, 20:883-896.
86. Jakobsson J., Lundberg C. Lentiviral vectors for use in the central nervous system. Mol. Ther. 2006, 13:484-493.
87. Jakobsson J., et al. Efficient transduction of neurons using Ross River glycoprotein-pseudotyped lentiviral vectors. Gene Ther. 2006, 13:966-973.
88. Johnson M.C. Mechanisms for Env glycoprotein acquisition by retroviruses. AIDS Res. Hum. Retroviruses 2011, 27:239-247.
89. Kafri T., et al. A packaging cell line for lentivirus vectors. J. Virol. 1999, 73:576-584.
90. Kaludov N., et al. Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J. Virol. 2001, 75:6884-6893.
91. Kantor B., et al. Notable Reduction in Illegitimate Integration Mediated by a PPT-deleted, Nonintegrating Lentiviral Vector. Mol. Ther. 2011, 19:547-556.
92. Kaplitt M.G., et al. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat. Genet. 1994, 8:148-154.
93. Kay M.A. AAV vectors and tumorigenicity. Nat. Biotechnol. 2007, 25:1111-1113.
94. Klages N., et al. A stable system for the high-titer production of multiply attenuated lentiviral vectors. Mol. Ther. 2000, 2:170-176.
95. Klein R.L., et al. Long-term actions of vector-derived nerve growth factor or brain-derived neurotrophic factor on choline acetyltransferase and Trk receptor levels in the adult rat basal forebrain. Neuroscience 1999, 90:815-821.
96. Koerber J.T., et al. Molecular evolution of adeno-associated virus for enhanced glial gene delivery. Mol. Ther. 2009, 17:2088-2095.
97. Kreppel F., Kochanek S. Long-term transgene expression in proliferating cells mediated by episomally maintained high-capacity adenovirus vectors. J. Virol. 2004, 78:9-22.
98. Krisky D.M., et al. Development of herpes simplex virus replication-defective multigene vectors for combination gene therapy applications. Gene Ther. 1998, 5:1517-1530.
99. Krisky D.M., et al. Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons. Gene Ther. 1998, 5:1593-1603.
100. Kumar M., et al. Systematic determination of the packaging limit of lentiviral vectors. Hum. Gene Ther. 2001, 12:1893-1905.
101. Lai Y., et al. Evidence for the failure of adeno-associated virus serotype 5 to package a viral genome > or = 8.2 kb. Mol. Ther. 2010, 18:75-79.
102. Lawlor P.A., et al. Efficient gene delivery and selective transduction of glial cells in the mammalian brain by AAV serotypes isolated from nonhuman primates. Mol. Ther. 2009, 17:1692-1702.
103. Leis J., et al. Standardized and simplified nomenclature for proteins common to all retroviruses. J. Virol. 1988, 62:1808-1809.
104. Lewis P.F., Emerman M. Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J. Virol. 1994, 68:510-516.
105. Lilley C.E., et al. Multiple immediate-early gene-deficient herpes simplex virus vectors allowing efficient gene delivery to neurons in culture and widespread gene delivery to the central nervous system in vivo. J. Virol. 2001, 75:4343-4356.
106. Liu J., et al. 3D visualization of HIV virions by cryoelectron tomography. Methods Enzymol. 2010, 483:267-290.
107. Lock M., et al. Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral vectors at scale. Hum. Gene Ther. 2010, 21:1259-1271.
108. Lou E. Oncolytic herpes viruses as a potential mechanism for cancer therapy. Acta Oncol. 2003, 42:660-671.
109. Lozier J.N., et al. Toxicity of a first-generation adenoviral vector in rhesus macaques. Hum. Gene Ther. 2002, 13:113-124.
110. Lundberg C., et al. Applications of lentiviral vectors for biology and gene therapy of neurological disorders. Curr. Gene Ther. 2008, 8:461-473.
111. Lusby E., et al. Nucleotide sequence of the inverted terminal repetition in adeno-associated virus DNA. J. Virol. 1980, 34:402-409.
112. Maier P., et al. Retroviral vectors for gene therapy. Future Microbiol. 2010, 5:1507-1523.
113. Marconi P., et al. Replication-defective herpes simplex virus vectors for gene transfer in vivo. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:11319-11320.
114. Marconi P., et al. HSV as a vector in vaccine development and gene therapy. Adv. Exp. Med. Biol. 2009, 655:118-144.
115. Markert J.M., et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 2000, 7:867-874.
116. Markert J.M., et al. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol. Ther. 2009, 17:199-207.
117. Markowitz D., et al. A safe packaging line for gene transfer: separating viral genes on two different plasmids. J. Virol. 1988, 62:1120-1124.
118. McCarty D.M., et al. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther. 2001, 8:1248-1254.
119. McCarty D.M., et al. Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu. Rev. Genet. 2004, 38:819-845.
120. McCown T.J. Adeno-Associated Virus (AAV) Vectors in the CNS. Curr. Gene Ther. 2011, 11:181-188.
121. Michelfelder S., Trepel M. Adeno-associated viral vectors and their redirection to cell-type specific receptors. Adv. Genet. 2009, 67:29-60.
122. Miller A.D. Cell-surface receptors for retroviruses and implications for gene transfer. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:11407-11413.
123. Mineta T., et al. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med. 1995, 1:938-943.
124. Miyoshi H., et al. Development of a self-inactivating lentivirus vector. J. Virol. 1998, 72:8150-8157.
125. Morral N., et al. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:12816-12821.
126. Morsy M.A., et al. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:7866-7871.
127. Muzyczka N., Warrington K.H. Custom adeno-associated virus capsids: the next generation of recombinant vectors with novel tropism. Hum. Gene Ther. 2005, 16:408-416.
128. Nakai H., et al. Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors. Nat. Biotechnol. 2000, 18:527-532.
129. Naldini L., et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996, 272:263-267.
130. Nash K., et al. Complete in vitro reconstitution of adeno-associated virus DNA replication requires the minichromosome maintenance complex proteins. J. Virol. 2008, 82:1458-1464.
131. Niemeyer G.P., et al. Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. Blood 2009, 113:797-806.
132. NIH Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines) http://oba.od.nih.gov/oba/rac/Guidelines/NIH_Guidelines.htm.
133. Oxford Biomedica Oxford BioMedica Announces Interim Data from Highest (5x) Dose Cohort in ProSavin® Phase I/II Study in Parkinson's Disease - 04/08/2011 http://www.oxfordbiomedica.co.uk/page.asp?pageid=59&newsid=297.
134. Pakzaban P., et al. Effect of exogenous nerve growth factor on neurotoxicity of and neuronal gene delivery by a herpes simplex amplicon vector in the rat brain. Hum. Gene Ther. 1994, 5:987-995.
135. Parks R.J. Improvements in adenoviral vector technology: overcoming barriers for gene therapy. Clin. Genet. 2000, 58:1-11.
136. Parks R.J., et al. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:13565-13570.
137. Pellett P.E., Roizman B. The Family Herpesviridae: A Brief Introduction. Fields Virology 2007, 2479-2499. Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia. D.M. Knipe, P.M. Howley (Eds.).
138. Philippe S., et al. Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:17684-17689.
139. Philpott N.J., Thrasher A.J. Use of nonintegrating lentiviral vectors for gene therapy. Hum. Gene Ther. 2007, 18:483-489.
140. Pike-Overzet K., et al. New insights and unresolved issues regarding insertional mutagenesis in X-linked SCID gene therapy. Mol. Ther. 2007, 15:1910-1916.
141. Rabinowitz J.E., et al. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 2002, 76:791-801.
142. Rahim A.A., et al. Efficient gene delivery to the adult and fetal CNS using pseudotyped non-integrating lentiviral vectors. Gene Ther. 2009, 16:509-520.
143. Rauschhuber C., et al. New insights into stability of recombinant adenovirus vector genomes in mammalian cells. Eur. J. Cell Biol 2011, 10.1016/j.ejcb.2011.01.006.
144. Reddy V.S., et al. Crystal structure of human adenovirus at 3.5 A resolution. Science 2010, 329:1071-1075.
145. Rivera V.M., et al. Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. Blood 2005, 105:1424-1430.
146. Robertson E.S., et al. Epstein-Barr virus vectors for gene delivery to B lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:11334-11340.
147. Roizman B., et al. Herpes Simplex Viruses. Fields Virology 2007, 2502-2601. Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia. D.M. Knipe, P.M. Howley (Eds.).
148. Rose J.A., et al. Structural proteins of adenovirus-associated viruses. J. Virol. 1971, 8:766-770.
149. Saeki Y., et al. Improved HSV-1 amplicon packaging system using ICP27-deleted, oversized HSV-1 BAC DNA. Methods Mol. Med. 2003, 76:51-60.
150. Samaniego L.A., et al. Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins. J. Virol. 1998, 72:3307-3320.
151. Samulski R.J., et al. Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J. Virol. 1989, 63:3822-3828.
152. Sarkis C., et al. Non-integrating lentiviral vectors. Curr. Gene Ther. 2008, 8:430-437.
153. Scarlata S., Carter C. Role of HIV-1 Gag domains in viral assembly. Biochim. Biophys. Acta 2003, 1614:62-72.
154. Schnepp B.C., et al. Characterization of adeno-associated virus genomes isolated from human tissues. J. Virol. 2005, 79:14793-14803.
155. Shen Y., Post L. Viral Vectors and Their Applications. Fields virology 2007, 539-564. Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia. B.N. Fields (Ed.).
156. Shen S., et al. Terminal N-Linked Galactose Is the Primary Receptor for Adeno-associated Virus 9. J. Biol. Chem. 2011, 286:13532-13540.
157. Shieh M.T., et al. Cell surface receptors for herpes simplex virus are heparan sulfate proteoglycans. J. Cell Biol. 1992, 116:1273-1281.
158. Snyder R.O., et al. In vitro resolution of covalently joined AAV chromosome ends. Cell 1990, 60:105-113.
159. Sommerfelt M.A. Retrovirus receptors. J. Gen. Virol. 1999, 80(Pt 12):3049-3064.
160. Spaete R.R., Frenkel N. The herpes simplex virus amplicon: a new eucaryotic defective-virus cloning-amplifying vector. Cell 1982, 30:295-304.
161. Stephen S.L., et al. Homologous and heterologous recombination between adenovirus vector DNA and chromosomal DNA. J. Gene Med. 2008, 10:1176-1189.
162. Stephen S.L., et al. Chromosomal integration of adenoviral vector DNA in vivo. J. Virol. 2010, 84:9987-9994.
163. Stieger K., et al. Detection of intact rAAV particles up to 6 years after successful gene transfer in the retina of dogs and primates. Mol. Ther. 2009, 17:516-523.
164. Strang B.L., Stow N.D. Circularization of the herpes simplex virus type 1 genome upon lytic infection. J. Virol. 2005, 79:12487-12494.
165. Straus S.E., et al. Concatemers of alternating plus and minus strands are intermediates in adenovirus-associated virus DNA synthesis. Proc. Natl. Acad. Sci. U. S. A. 1976, 73:742-746.
166. Summerford C., Samulski R.J. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol. 1998, 72:1438-1445.
167. Sun L., et al. Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization. Nat. Med. 2000, 6:599-602.
168. Sun M., et al. Correction of a rat model of Parkinson's disease by coexpression of tyrosine hydroxylase and aromatic amino acid decarboxylase from a helper virus-free herpes simplex virus type 1 vector. Hum. Gene Ther. 2003, 14:415-424.
169. Sun M., et al. Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease. Brain Res. 2005, 1052:119-129.
170. Suzuki T., et al. Development of a recombinant adenovirus vector production system free of replication-competent adenovirus by utilizing a packaging size limit of the viral genome. Virus Res. 2011, 158:154-160.
171. Tattersall P., Ward D.C. Rolling hairpin model for replication of parvovirus and linear chromosomal DNA. Nature 1976, 263:106-109.
172. Taymans J.M., et al. Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain. Hum. Gene Ther. 2007, 18:195-206.
173. Telesnitsky A., Goff S.P. Reverse Transcriptase and the Generation of Retroviral DNA. Retroviruses 1997, Cold Spring Harbor Laboratory Press, Cold Spring Harbor (NY). C. J.M. (Ed.).
174. Thomas C.E., et al. Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain. Mol. Ther. 2001, 3:36-46.
175. Thomas C.E., et al. Adenovirus binding to the coxsackievirus and adenovirus receptor or integrins is not required to elicit brain inflammation but is necessary to transduce specific neural cell types. J. Virol. 2002, 76:3452-3460.
176. Tomko R.P., et al. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:3352-3356.
177. Tuszynski M.H., et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat. Med. 2005, 11:551-555.
178. Van der Perren A., et al. Efficient and stable transduction of dopaminergic neurons in rat substantia nigra by rAAV 2/1, 2/2, 2/5, 2/6.2, 2/7, 2/8 and 2/9. Gene Ther. 2011, 18:517-527.
179. Van Vliet K.M., et al. The role of the adeno-associated virus capsid in gene transfer. Methods Mol. Biol. 2008, 437:51-91.
180. Vandenberghe L.H., et al. Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid. Nat. Med. 2006, 12:967-971.
181. Vandenberghe L.H., et al. Efficient serotype-dependent release of functional vector into the culture medium during adeno-associated virus manufacturing. Hum. Gene Ther. 2010, 21:1251-1257.
182. Volpers C., Kochanek S. Adenoviral vectors for gene transfer and therapy. J. Gene Med. 2004, 6(Suppl. 1):S164-S171.
183. Wadsworth S., et al. Anatomy of herpes simplex virus DNA. II. Size, composition, and arrangement of inverted terminal repetitions. J. Virol. 1975, 15:1487-1497.
184. Wang C., et al. Recombinant AAV serotype 1 transduction efficiency and tropism in the murine brain. Gene Ther. 2003, 10:1528-1534.
185. Weiss R.A., Tailor C.S. Retrovirus receptors. Cell 1995, 82:531-533.
186. Wiley Gene Therapy Clinical Trials Worldwide 2011, http://www.wiley.com//legacy/wileychi/genmed/clinical/.
187. Wolfe J.H., et al. Herpesvirus vector gene transfer and expression of beta-glucuronidase in the central nervous system of MPS VII mice. Nat. Genet. 1992, 1:379-384.
188. Wong L.F., et al. Lentivirus-mediated gene transfer to the central nervous system: therapeutic and research applications. Hum. Gene Ther. 2006, 17:1-9.
189. Wu N., et al. Prolonged gene expression and cell survival after infection by a herpes simplex virus mutant defective in the immediate-early genes encoding ICP4, ICP27, and ICP22. J. Virol. 1996, 70:6358-6369.
190. Wu Z., et al. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol. Ther. 2006, 14:316-327.
191. Wu Z., et al. Alpha2,3 and alpha2,6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6. J. Virol. 2006, 80:9093-9103.
192. Wu Z., et al. Effect of genome size on AAV vector packaging. Mol. Ther. 2010, 18:80-86.
193. Xiao W., et al. Gene therapy vectors based on adeno-associated virus type 1. J. Virol. 1999, 73:3994-4003.
194. Xie Q., et al. The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:10405-10410.
195. Yamada M., et al. Herpes simplex virus vector-mediated expression of Bcl-2 prevents 6-hydroxydopamine-induced degeneration of neurons in the substantia nigra in vivo. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:4078-4083.
196. Yan Z., et al. Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:6716-6721.
197. Yanez-Munoz R.J., et al. Effective gene therapy with nonintegrating lentiviral vectors. Nat. Med. 2006, 12:348-353.
198. Zhang G.R., et al. A tyrosine hydroxylase-neurofilament chimeric promoter enhances long-term expression in rat forebrain neurons from helper virus-free HSV-1 vectors. Brain Res. Mol. Brain Res. 2000, 84:17-31.
199. Zufferey R., et al. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat. Biotechnol. 1997, 15:871-875.
200. Zufferey R., et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol. 1998, 72:9873-9880.